Targeting SARS-CoV-2 main protease (3CLpro) with Paeonia-derived phytochemicals
In Silico Pharmacology · 17.04.2026 · 14 (2)
DOI: 10.1007/s40203-026-00630-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Silico Pharmacology, online erschienen am 17.04.2026. Verfasst von Cemal Sandalli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211 USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.
Abstract (Originalsprache)
Coronavirus Disease 19 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), stimulated intensive drug-development efforts throughout the world. As COVID-19 has become endemic in many regions of the world, phytochemicals used in ethnomedicine may have utility in the prevention or treatment of COVID-19. Here, we employed machine learning/deep learning drug discovery tools to evaluate compounds previously identified in roots of plants of the Paeonia genus for their drug-like properties and potential to inhibit 3CL pro , the main protease of SARS-CoV2. Our results identify Paeonia-derived compounds that have favorable drug-like properties and are predicted to have a high binding affinity for 3CL pro . Molecular dynamics simulations supported the binding affinity of Paeonia-derived compounds for 3CL pro . We validated these in silico computational results by experimentally determining the 50% inhibitory concentration (IC 50 ) of two Paeonia-derived compounds, paeoniflorigenone and 3- O -methylquercetin, using purified 3CL pro with baicalein as a control. The IC 50 values for paeoniflorigenone, 3- O -methylquercetin and baicalein were 9.33 µM, 43.94 and 43.85 µM, respectively. Root extracts from five Paeonia species were found to have minimal cytotoxicity against three different human cell types. Our results represent a proof-of-concept study demonstrating that in silico techniques, including machine and deep learning methods, can be used to identify phytochemicals as starting points for the discovery of antiviral compounds against SARS-CoV-2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211 USA.
- Department of Biological Sciences, Middle East Technical University, 06800 Ankara, Türkiye.
- Department of Biology, Karadeniz Technical University, 61080 Trabzon, Türkiye.
- Department of Chemistry, Recep Tayyip Erdogan University, 53100 Rize, Türkiye.
- Technology Division, Joint BioEnergy Institute, Emeryville, CA 94608 USA.
- Department of Stem Cell Research, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, 31441 Dammam, Saudi Arabia.
ORCID-Profile: Mark Hannink
Förderung
- Karolinska Institute
Zitieren
APA
Sandalli, C., Bostancioglu, S. M., Sandalli, A., Turumtay, E. A., Almohazey, D., Alsaeed, M., Alhamid, G., Rabaan, A. A., Turumtay, H., Ami, E. I., Lorson, C. L., Hannink, M., Singh, K., & Tombuloglu, H. (2026). Targeting SARS-CoV-2 main protease (3CLpro) with Paeonia-derived phytochemicals. In Silico Pharmacology, 14(2). https://doi.org/10.1007/s40203-026-00630-7
Vancouver
Sandalli C, Bostancioglu SM, Sandalli A, Turumtay EA, Almohazey D, Alsaeed M, et al. Targeting SARS-CoV-2 main protease (3CLpro) with Paeonia-derived phytochemicals. In Silico Pharmacology. 2026;14(2). doi:10.1007/s40203-026-00630-7
BibTeX
@article{Sandalli2026,
author = {Sandalli, Cemal and Bostancioglu, Safiye Merve and Sandalli, Aytul and Turumtay, Emine Akyuz and Almohazey, Dana and Alsaeed, Moneerah and Alhamid, Galyah and Rabaan, Ali A and Turumtay, Halbay and Ami, Ei-Ichi and Lorson, Christian L and Hannink, Mark and Singh, Kamal and Tombuloglu, Huseyin},
title = {Targeting SARS-CoV-2 main protease (3CLpro) with Paeonia-derived phytochemicals},
journal = {In Silico Pharmacology},
year = {2026},
volume = {14},
number = {2},
doi = {10.1007/s40203-026-00630-7}
}
EUVIMED